β-blocker use and incidence of chronic obstructive pulmonary disease exacerbations;Uso de bloqueadores-β y la incidencia de exacerbaciones de la enfermedad obstructiva pulmonar crónica

Annals of Pharmacotherapy

Volumn 47, Issue 5, 2013, Pages 651-656

  Farland, Michelle Z ^a   Peters, Cassey J ^a   Williams, Juli D ^a   Bielak, Kenneth M ^a   Heidel, R Eric ^a   Ray, Shaunta' M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; TIOTROPIUM BROMIDE; XANTHINE DERIVATIVE;

ADULT; ARTICLE; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

EID: 84877095853     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R600     Document Type: Article

References (18)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2011. www.goldcopd.org/ (accessed 2012 Sept 7).
2. Andrus MR, Holloway KP, Clark DB. Use of β-blockers in patients with COPD. Ann Pharmacother 2004;38:142-5. doi: 10.1345/aph.1D113
3. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005;98:493-7. doi: 10.1093/qumed/hci080
4. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008;101:353-8. doi: 10.1016/j.amjcard.2007.08.046
5. Dransfield MT, Rowe SM, Johnson JE, Bailey W, Gerald L. Use of betablockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5. doi: 10.1136/thx.2007.081893
6. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of β-blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549. doi: 10.1136/bmj.d2549
7. Rutten FH, Zuithoff NP, Hak E, Grobbee D, Hoes A. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7. doi: 10.1001/archinternmed.2010.112
8. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective betablockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008;178:695-700. doi: 10.1164/rccm.200803-384OC
9. Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking p-blockers. Pharmacotherapy 2007;27:684-90. doi: 10.1292/phco.27.5.684
10. Barnett MJ, Milavetz G, Kaboli PJ. β-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy 2005;25:1550-9. doi: 10.1592/phco.2005.25.11.1550
11. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease of asthma. J Am Coll Cardiol 2001;37:1950-6. doi: 10.1016/S0735-1097(01)01225-6
12. Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic cor pulmonale in COPD. Int J Chron Obstruct Pulmon Dis 2007;2:273-82.
13. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:20-2. doi: 10.1513/pats.200407-037MS
14. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD003566.
15. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84. doi: 10.1136/thoraxjnl-2012-201945
16. Lin R, Peng H, Nguyen LP, et al. Changes in beta 2-adrenoreceptor and other signaling proteins produced by chronic administration of "betablockers" in a murine asthma model. Pulm Pharmacol Ther 2008;21: 115-24. doi: 10.1016/j.pupt.2007.06.003
17. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002;21:1290-5. doi: 10.1016/S1053-2498(02)00459-X
18. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127:818-24. doi: 10.1378/chest.127.3.818